As a global leader in urology, we have a rich portfolio of new medicines, considered by some to be among the strongest in the industry.
Urology makes up a significant proportion of primary care consultations.¹ The most common conditions include those that affect bladder and prostate functions.
Astellas has a proven track record in urology. We offer a choice of treatment options for patients with overactive bladder syndrome (OAB), which affects around 17% of people in Europe and can cause urinary incontinence in over a third of patients.² We also have a range of treatments for lower urinary tract symptoms (LUTs) associated with benign prostatic hyperplasia (BPH). LUTs can occur in up to 30% of men over the age of 65 years, and the symptoms they deal with can have a significant impact on their quality of life, one of the most frequent being nocturia (urinary frequency at night).³
1. Arya M, Shergill IS, Silhi N, Grange P, Bott SRJ. Essential Urology in General Practice. Published by Quay Books, MA Healthcare Ltd.
2. Milsom I, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87(9)760-6.
3. Rosette de la, J, et al. Guidelines on Benign Prostatic Hyperplasia.
Learn more about our therapy areas:
Innovative therapies in preventing organ rejection after transplantation
World-leading approach in R&D to satisfy unmet patient needs in urological conditions
Our commitment is to developing first-in-class and best-in-class therapies
Addressing the complex challenges of serious fungal and bacterial infections
Pioneering treatments that effectively manage chronic pain